- Report
- December 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- January 2025
- 138 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- October 2024
- 319 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- April 2022
- 315 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- February 2022
- 421 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- February 2024
- 160 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- October 2023
- 175 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2023
- 88 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- October 2019
- 472 Pages
The Oral Protein Drug Delivery market is a rapidly growing sector of the pharmaceutical industry. It involves the delivery of proteins, peptides, and other macromolecules through the oral route. This method of drug delivery has several advantages over traditional methods, such as improved patient compliance, reduced side effects, and improved bioavailability. It also offers the potential for targeted delivery of drugs to specific sites in the body.
The Oral Protein Drug Delivery market is driven by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases. Additionally, the development of novel technologies, such as nanotechnology, has enabled the development of more efficient and targeted delivery systems.
Some of the major players in the Oral Protein Drug Delivery market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. These companies are actively involved in the development of novel drug delivery systems, as well as the production and marketing of existing products. Show Less Read more